Within our Radiopharmaceutical Therapy (RPT) capability, we bring together radiochemistry, preclinical imaging, in vivo biology and translational expertise into a single, commercially-focused unit built for efficiency and reliability. Our industry-experienced team supports biotech and pharma radiopharmaceuticals developers during preclinical discovery and development.
From target validation and radiochemistry optimisation through biodistribution, dosimetry and efficacy studies in validated models. With industry‑validated platforms, regulatory‑aligned workflows and a specialist team operating within high-capacity licensed facilities, we provide a seamless, end‑to‑end service that reduces complexity, shortens timelines, and strengthens the evidence behind every programme.
See FAQs
clinical trials supported through our validated preclinical datasets
radiochemical purity for complex alpha and beta-emitting conjugates
regulatory aligned workflows
industry experts driving rapid translational innovation
compounds supported to clinic
assays supporting clinical development
We help clients make key decisions to progress by offering end-to-end integration of entire radiopharmaceutical evaluation and development into Phase 0 and Phase 1 studies.

Objective IND: A linear flow showing the 7 stages of development to IND
With gamma, beta and alpha-emitting radiometals of small molecules (e.g., FAPI, PSMA), peptides, proteins and other biologics containing chelators such as DOTA, DOTAM, Macropa, and DFO/DFO*. Experience in a variety of purification methods (e.g., ultrafiltration, SPE), QC analysis (HPLC, ITLC, gamma spectrometry), and conjugation techniques.
Discover moreUtilising CDX and PDX models to deliver high-resolution longitudinal tumour growth inhibition (TGI) data and PK/PD analysis.
Discover more
Quantitative time-course activity analysis across 15+ organ systems using PET, SPECT and CT imaging, EBRT, US, Gamma counting and PK modelling.
Discover morePrecise calculation of absorbed doses (Voxel/MIRD) to provide reliable preclinical-to-clinical dose extrapolation.
Discover more
Strategic pairing of diagnostic/therapeutic isotopes (e.g. 89Zr and 177Lu) to build companion imaging and patient-selection strategies.
Discover moreHigh-throughput screening for affinity, internalisation, and stability to identify lead candidates faster.
Discover more
Detailed cellular phenotyping through high-resolution autoradiography, gamma counting, and IHC correlation.
Discover moreWe ensure your data transitions seamlessly from the bench to the patient. Through our partnership network and in-house expertise, we provide:
Accelerating your path to the clinic with the precision, speed, and reliability required to make key decisions, de-risk your program and secure clinical momentum.
In the complex landscape of radiochemistry and translational imaging, the difference lies in the hands behind the science.
Our team comprises industry-leading specialists across preclinical services and radiopharmaceuticals, dedicated to bridging the gap between early discovery and clinical success.
Meet the experts who turn sophisticated data into actionable therapeutic insights.
Explore our scientific expertiseReady to bring momentum to your radiopharmaceutical program?
Our experts are here to support your journey from concept to clinic. Contact our team to discuss a tailored solution.
Fill in the form today and speak to us to see how we can help advance your drug discovery project.